Indy Hematology Education publishes consensus paper on cancer trial diversity

Indy Hematology Education has published a new consensus document in Wiley’s Diversity & Inclusion Research journal aimed at reducing the underrepresentation of Black and minority patients in oncology clinical trials. The paper gives healthcare organizations, academic centers and drug sponsors a framework to make cancer research more equitable and improve the quality of real-world safety and efficacy data.

Why it matters: - Black and minority patients have been underrepresented in the clinical trials that support approval of modern cancer therapies. - That gap can leave drugmakers and clinicians with incomplete safety and efficacy data for the populations they treat. - The new recommendations aim to change trial design and participation patterns at the system level.

What happened: - Indy Hematology Education announced the publication of "Indianapolis Consensus Recommendations for Promoting Diversity and Equity in Cancer Clinical Trials: 'The Indianapolis Black Paper'." - Wiley’s peer-reviewed journal, Diversity & Inclusion Research, published the paper on July 13, 2026. - Dr. Ruemu Birhiray, president and CEO of Indy Hematology Education, authored the document.

The details: - The paper sets out an immediate framework for healthcare organizations, academic medical centers and pharmaceutical sponsors. - The framework is designed to help those groups build more equitable clinical trial structures. - The recommendations are described as strict and standardized rather than general discussion of health disparities. - Indy Hematology Education says the paper is a foundational consensus document aimed at correcting systemic minority underrepresentation in oncology research. - The full recommendations are available through the Wiley Online Library and official Indy Hematology Education channels.

Between the lines: - The publication reflects a shift from awareness-building to operational guidance. - The paper’s focus on standardized recommendations suggests the next challenge is implementation across sponsors, trial sites and academic centers. - Dr. Birhiray said the oncology community needs to address trial diversity gaps now to ensure future cancer research reflects patient demographics.

What's next: - Healthcare networks, research institutions and industry stakeholders can begin using the consensus recommendations in trial planning and recruitment. - The paper may serve as a reference point for broader equity efforts in oncology research. - Indy Hematology Education is positioning the publication as part of its broader advocacy for health equity and clinical excellence.

The bottom line: - The Indianapolis Black Paper turns a long-running equity problem in cancer research into a concrete action plan for the industry.